![]() |
|
|
Vol. 281, Issue 1, 93-102, 1997
Department of Anaesthesia and Pain Management, We studied healthy men who underwent blood sampling for plasma
nandrolone, testosterone and inhibin measurements before and for 32 days after a single i.m. injection of 100 mg of nandrolone ester in
arachis oil. Twenty-three men were randomized into groups receiving
nandrolone phenylpropionate (group 1, n = 7) or
nandrolone decanoate (group 2, n = 6) injected into
the gluteal muscle in 4 ml of arachis oil vehicle or nandrolone
decanoate in 1 ml of arachis oil vehicle injected into either the
gluteal (group 3, n = 5) or deltoid (group 4, n = 5) muscles. Plasma nandrolone, testosterone and
inhibin concentrations were analyzed by a mixed-effects indirect
response model. Plasma nandrolone concentrations were influenced
(P < .001) by different esters and injection sites, with higher
and earlier peaks with the phenylpropionate ester, compared with the
decanoate ester. After nandrolone decanoate injection, the highest
bioavailability and peak nandrolone levels were observed with the 1-ml
gluteal injection. Plasma testosterone concentrations were also
influenced (P < .001) by the ester and injection site, with the
most rapid, but briefest, suppression being due to the phenylpropionate
ester, whereas the most sustained suppression was achieved with the
1-ml gluteal injection. Plasma inhibin concentrations were also
significantly influenced by injection volume and site, with the lowest
nadir occurring after the nandrolone decanoate 1-ml gluteal injection.
Thus, the bioavailability and physiological effects of a nandrolone
ester in an oil vehicle are greatest when the ester is injected in a
small (1 ml vs. 4 ml) volume and into the gluteal
vs. deltoid muscle. We conclude that the side-chain
ester and the injection site and volume influence the pharmacokinetics
and pharmacodynamics of nandrolone esters in an oil vehicle in men.
Copyright © by The American Society for Pharmacology and Experimental Therapeutics